Previous 10 | Next 10 |
home / stock / dsnky / dsnky news
2023-07-13 11:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Japan drove internatio...
2023-07-12 07:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Japan drove internatio...
2023-05-26 03:13:14 ET Summary Daiichi Sankyo is leading the world in the development of antibody-drug conjugates, which are finally paying off in cancer after more than a decade of ups and downs. The company stands poised to continue to stretch its arms in the space and reap sign...
2023-05-01 15:40:06 ET Daiichi Sankyo Company, Limited (DSKYF) Q4 2022 Results Conference Call April 27, 2023 04:30 AM ET Company Participants Hiroyuki Okuzawa - Head, Corporate Planning and Management Division, CFO Ken Takeshita - Global Head of Research and Develop...
2023-04-21 11:32:43 ET The US FDA has extended by three months its review of Daiichi Sankyo's ( OTCPK:DSKYF ) NDA for quizartinib for newly diagnosed acute myeloid leukemia (AML). The new agency action date is July 24. The reason for the extra time is that the agency needs...
2023-04-20 12:12:30 ET Summary BMEZ launched right before Covid, riding up the boost when speculative growth took off. In 2022, the story was much different, and the fund struggled significantly. This fund is much riskier than its older sister fund, BME, but it also can provid...
2023-03-16 09:07:22 ET Esperion Therapeutics ( NASDAQ: ESPR ) continued the post-market selloff on Thursday due to a payment dispute with Daiichi Sankyo ( OTCPK:DSNKY ) over its cholesterol-lowering agent bempedoic acid, prompting Bank of America to downgrade the stock. ...
Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...
Daiichi Sankyo's ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) said that the U.S. Patent and Trademark Office (PTO) granted its request to re-institute post-grant review (PGR) of the patentability of certain claims of Seagen's ( NASDAQ: SGEN ) U.S. patent 10,808,039. "We are very pleas...
Summary As a leader in various therapeutic areas, the company's total revenue was $7,042 million in the third quarter of 2022, up 12.5% quarter-on-quarter. Gilead will be required to make royalties of 3% on future sales of Biktarvy and bictegravir-containing medicines up to the 4th quar...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...